European CHMP recommends approval of Cabazitaxel Accord for the treatment of hormone refractory metastatic prostate cancer

Cabazitaxel Accord is a hybrid medicine of Jevtana, containing the same active substance but available in a different formulation (20 mg/ml concentrate for solution for infusion). Studies have demonstrated its satisfactory quality and its bioequivalence to Jevtana.


European Medicines Agency